SanBio Co Stock

SanBio Co Debt/EBITDA

The Total Debt to EBITDA Ratio of SanBio Co (4592.T) as of Aug 16, 2026 is -0.11. In the previous year, Total Debt to EBITDA Ratio was -0.15 — a change of -22.92% (higher).

Debt/EBITDA

-0.11

YoY

-22.92%

Last updated:

Total Debt to EBITDA Ratio of SanBio Co is 2026 -0.11 . Total Debt to EBITDA Ratio of SanBio Co was 2025 -0.15 . It decreases by -22.92% higher compared to the previous year.
Access this data via the Eulerpool API

SanBio Co Stock analysis

What does SanBio Co do? SanBio Co Ltd is a leading bio-pharmaceutical company focused on the development of products for the treatment of serious neurological diseases. The company was founded in Japan in 2000 and has since become a multinational company with offices in the USA and Europe. Answer: SanBio Co Ltd is a bio-pharmaceutical company that specializes in developing products for the treatment of serious neurological diseases. It was founded in Japan in 2000 and has expanded to become a multinational company with offices in the USA and Europe. SanBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SanBio Co stock

Total Debt to EBITDA Ratio of SanBio Co is -0.11 in 2026.

Total Debt to EBITDA Ratio of SanBio Co changed from -0.15 to -0.11, representing a -22.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio SanBio Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's SanBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — SanBio Co

All Key Metrics — SanBio Co